April 22 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:
* BIOHAVEN ANNOUNCES ROBUST CLINICAL DATA WITH SINGLE DOSE RIMEGEPANT THAT DEFINES ACUTE AND DURABLE BENEFITS TO PATIENTS
* BIOHAVEN PHARMACEUTICAL HOLDING SAYS BROAD AND CLINICALLY IMPORTANT BENEFITS BEYOND INITIAL REGISTRATIONAL ENDPOINTS ARE NOW REPORTED.
* BIOHAVEN- RIMEGEPANT FIRST ORAL CGRP RECEPTOR ANTAGONIST TO DELIVER POSITIVE DATA ON PAIN FREEDOM IN TWO PIVOTAL PHASE 3 TRIALS IN ACUTE TREATMENT OF MIGRAINE Source text for Eikon: Further company coverage:
